Skip to main content

Advertisement

Fig. 5 | Clinical Epigenetics

Fig. 5

From: Epigenetics in cancer therapy and nanomedicine

Fig. 5

Schematic representation of the different types of nanocarriers for epigenetic therapy in cancer. a Vehicles for transport and delivery of iDNMTs in poly(lactic-co-glycolic acid) (PLGA)- and poly(ethylene glycol) (PEG)-based nanomicelles, in gelatinase with PEG and poly-ε-caprolactone (PCL), and in alendronate-PEG-2-distearoyl-sn-glycero-3-phosphoethanolamine (DSPE). b Vehicles for transport and delivery of iHDACs in hyaluronic acid (HA)-coated cationic solid lipid (SL) nanoparticles (didecyldimethyl ammonium bromide (DDAB) is used as cationic lipid), in micelles based on SAHA-based prodrug polymer (POEG-b-PSAHA) (POEG: poly(oligo(ethylene glycol) methacrylate)), and in a PLGA-lecithin-PEG core-shell system (DSPE: 1,2-dioctadecanoyl-sn-glycero-3-phosphoethanolamine). c Vehicles for transport and delivery of siRNA in cationic cyclodextrin-based polymer (CDP) modified with a terminal adamantane group (AD-PEG) and some AD-PEG conjugated to human transferrin (Th), in PEGylated liposomes, in single-walled nanotubes (SWNTs) functionalized with PEG-DSPE and polymer poly(allylamine hydrochloride) (PAH), and in exosome-based systems

Back to article page